Neoadjuvant therapy for resectable pancreatic cancer
Authors:
- Douglas B. EvansDEDouglas B. Evans
- Christopher H. CraneCCChristopher H. Crane
- Peter W.T. PistersPPPeter W.T. Pisters
- Robert A. WolffRWRobert A. Wolff
- 31 October 2004
- journal article
- review article
- Published by Elsevier in Surgical Oncology Clinics of North America
- Vol. 13 (4) , 639-661
Abstract
No abstract availableKeywords
This publication has 79 references indexed in Scilit:
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II StudyJournal of Clinical Oncology, 2002
- Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the PancreasAnnals of Surgical Oncology, 2001
- Neoadjuvant Chemoradiotherapy for Adenocarcinoma of the Pancreas: Treatment Variables and Survival DurationAnnals of Surgical Oncology, 2001
- Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreasEuropean Journal of Surgical Oncology, 2000
- Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamoleJournal of Gastrointestinal Surgery, 1998
- Resection Margins in Carcinoma of the Head of the PancreasAnnals of Surgery, 1993
- Patterns of failure after curative resection of pancreatic carcinomaCancer, 1990
- Survival after Postoperative Combination Treatment of Rectal CancerNew England Journal of Medicine, 1986
- Prolongation of the Disease-Free Interval in Surgically Treated Rectal CarcinomaNew England Journal of Medicine, 1985